Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | BRAF | P15056 | 16/20 | 0.60 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | PIR | O00625 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | STK16 | O75716 | 1/20 | 0.53 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | FES | P07332 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912842 | 0.92 | BRAF (0.56) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL29796692 | 0.92 | BRAF (0.56) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL20399239 | 0.91 | BRAF (0.53) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL1443283 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL1437566 | 0.90 | FABP4 (0.51) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL20408716 | 0.89 | BRAF (0.52) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL855654 | 0.89 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL1492058 | 0.87 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL22832136 | 0.87 | BRAF (0.55) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL12468027 | 0.87 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113968803-B | Method for synthesizing 2, 6-difluoro-3-propyl sulfonamide benzoic acid | 苏州匠化生物科技有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-113968803-A | Novel method for synthesizing 2, 6-difluoro-3-propyl sulfonamide benzoic acid | 苏州匠化生物科技有限公司 | 2022-01-25 | — | — | CN | claimed |
| EP-3478684-B1 | NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB | FERMION OY (FI) | 2020-04-15 | — | — | EP | claimed |
| US-10407427-B2 | Processes for the preparation of Vemurafenib | FERMION OY (FI) | 2019-09-10 | — | — | US | claimed |
| US-20190194197-A1 | NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB | FERMION OY (FI) | 2019-06-27 | — | — | US | claimed |
| US-20180334457-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | SHILPA MEDICARE LIMITED (IN) | 2018-11-22 | — | — | US | claimed |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| CN-114026073-B | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-3746437-B1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-08-21 | — | — | EP | disclosed |
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-04-11 | — | — | US | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11731968-B2 | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2023-08-22 | — | — | US | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009012283-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012283-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAP3K4, MAP4K1 | CYP3A4 971/4885CYP2C9 2756/4885CYP2C19 4255/4885 |
| US-10407427-B2 | Processes for the preparation of Vemurafenib | BRAF, NRAS, PDCD1 | CYP3A4 1038/4885CYP2C9 595/4885CYP2C19 610/4885 |
| US-11731968-B2 | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP4K1, MAP4K4 | CYP3A4 764/4885CYP2C9 3266/4885CYP2C19 4058/4885 |
| US-20190194197-A1 | NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB | BRAF, RAF1, NRAS | CYP3A4 781/4885CYP2C9 526/4885CYP2C19 599/4885 |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | CYP3A4 971/4885CYP2C9 2756/4885CYP2C19 4255/4885 |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | CYP3A4 971/4885CYP2C9 2756/4885CYP2C19 4255/4885 |
| US-20180334457-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | BRAF, RAF1, NRAS | CYP3A4 701/4885CYP2C9 233/4885CYP2C19 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.